APA (7th ed.) Citation

Schumann, K., Klespe, K. C., Mauch, C., Loquai, C., Schultheis, U., Börger, S., . . . Posch, C. (2025). Switching PD‐1 to BRAF + MEK inhibition improves recurrence‐free survival in patients receiving a second course of adjuvant melanoma therapy. Wiley. https://doi.org/10.1111/jdv.20708

Chicago Style (17th ed.) Citation

Schumann, Katharina, et al. Switching PD‐1 to BRAF + MEK Inhibition Improves Recurrence‐free Survival in Patients Receiving a Second Course of Adjuvant Melanoma Therapy. Wiley, 2025. https://doi.org/10.1111/jdv.20708.

MLA (9th ed.) Citation

Schumann, Katharina, et al. Switching PD‐1 to BRAF + MEK Inhibition Improves Recurrence‐free Survival in Patients Receiving a Second Course of Adjuvant Melanoma Therapy. Wiley, 2025. https://doi.org/10.1111/jdv.20708.